Adjuvant treatment for stage II and III Colon Cancer. Ramon Salazar Catalan Institute of Oncology
|
|
- Esmond Ford
- 6 years ago
- Views:
Transcription
1 Adjuvant treatment for stage II and III Colon Cancer Ramon Salazar Catalan Institute of Oncology
2 Disclosures R. Salazar has served in a consultant or advisory role for Amgen, Merck Serono, Taihoo, MSD, Lylli, BMS, Roche Dx and enjoyed research funding for Roche Dx, Roche Pharma and Merck Serono
3 Outline History (recent ) Key Trials Stage II 3 vs 6 months (Stage III) Elderly
4 The evolution of treatment of early colon cancer 5-FU/Lev better than surgery alone (Moertel et al) 1990
5 The evolution of treatment of early colon cancer 5-FU/Lev better than surgery alone (Moertel et al) FU/LV better than surgery alone (IMPACT) 1994
6 The evolution of treatment of early colon cancer 5-FU/Lev better than surgery alone (Moertel et al) 1990 HDLV = LDLV 5-FU/LV better than 5-FU/Lev 6mo = 12mo Lev unnecessary Weekly = monthly FU/LV better than surgery alone (IMPACT) 1994
7 The evolution of treatment of early colon cancer 5-FU/Lev better than surgery alone (Moertel et al) 1990 HDLV = LDLV 5-FU/LV better than 5-FU/Lev 6mo = 12mo Lev unnecessary Weekly = monthly FU/LV better than surgery alone (IMPACT) 1994 LV5FU2 = monthly bolus (André et al) 2002
8 The evolution of treatment of early colon cancer 5-FU/Lev better than surgery alone (Moertel et al) 1990 HDLV = LDLV 5-FU/LV better than 5-FU/Lev 6mo = 12mo Lev unnecessary Weekly = monthly 1998 FOLFOX better than LV5FU2 (MOSAIC) FLOX better than 5-FU/LV (NSABP C-07) 2004/ FU/LV better than surgery alone (IMPACT) 1994 LV5FU2 = monthly bolus (André et al) 2002
9 The evolution of treatment of early colon cancer 5-FU/Lev better than surgery alone (Moertel et al) 1990 HDLV = LDLV 5-FU/LV better than 5-FU/Lev 6mo = 12mo Lev unnecessary Weekly = monthly 1998 FOLFOX better than LV5FU2 (MOSAIC) FLOX better than 5-FU/LV (NSABP C-07) 2004/ FU/LV better than surgery alone (IMPACT) FULV2 = monthly bolus (André et al) 2002 Xeloda 5-FU/LV (X-ACT) 2008 XelOx better than 5-FU/LV (NO16968) 2009
10 OS estimate OS estimate Adjuvant therapy increases the chance of survival: evidence in 20,898 CC patients (ACCENT 18 trials 5FU based) Stage II CC Stage III CC p= p< Surgery alone 8-year OS rate (95% CI): 66.8% (63.7% to 70.0%) Surgery + FU-based chemotherapy 8-year OS rate (95% CI): 72.2% (69.3% to 75.2%) Follow-up time (years) CC=colon cancer OS=overall survival Surgery alone 8-year OS rate (95% CI): 42.7% (39.9% to 45.7%) Surgery + FU-based chemotherapy 8-year OS rate (95% CI): 53.0% (50.2% to 55.9%) Follow-up time (years) Sargent, et al. JCO 2009
11 Early DFS predicts long-term survival after adjuvant therapy 2- and 3-year DFS predicts 5- and 6-year overall survival Correlation stronger in patients with stage III disease Correlation coefficient Overall survival (all patients) Overall survival (stage III disease) DFS 5-year 6-year 5-year 6-year 2-year year = perfect correlation Sargent et al. ASCO 2009
12 Key trials in the 21 st century X-ACT Xeloda vs 5FU bolo (Mayo) MOSAIC FOLFOX4 vs LV5FU2 infusion NSABP C-07 FLOX vs 5FULV bolus NO16968 XELOX vs 5FULV bolus (500 mg/m2 weekly x6/8 wk RPark) CALGB 89803, ACCORD 2, PETACC-3 5FU vs FOLFIRI NSABP C-08 mfolfox6 vs mfolfox6 + Bevacizumab AVANT FOLFOX4 vs FOLFOX4 + Avastin vs XELOX + Bevacizumab QUASAR-2 Capecitabine ± bevacizumab PETACC 8 Cetuximab + Folfox vs Folfox NCCTG (North Central Cancer Treatment Group) N0147 trial. Cetuximab + FLOX vs FLOX
13 Phase III Capecitabine vs bolus IV 5-FU/LV in adjuvant colon cancer (randomized) (X-ACT) M66001 Fully resected Stage III colon cancer < 8 weeks prior to study entry R A N D O Capecitabine twice-daily 1250 mg/m 2, D1-14 Q3W Ability to be followed > 5 years after the last patient is randomized M IZ A TI O N Leucovorin 20 mg/m 2 IV, D1-5 Q4W 5-FU 425 mg/m 2 IV bolus, D1-5 Q4W Primary endpoint: Planned sample size: Non-Inferiority in Disease-Free Survival 1956 pts
14 non- inferiority proven & trend to superior DFS with Capecitabine Estimated probability year DFS (%) Xeloda (n=1004) FU/LV (n=983) HR=0.88 (95% CI: ) p= ITT population Absolute difference at 5 years: 4.1% Years Twelves et al. ASCO GI 2008
15 trend to superior OS with Capecitabine Estimated probability year overall survival (%) Xeloda (n=1004) FU/LV (n=983) HR=0.86 (95% CI: ) p= Absolute difference at 5 years: 3.0% Years ITT population Twelves et al. ASCO GI 2008
16 X-ACT: safety Patients (%) Grade 3/4 AEs Xeloda (n=993) 5-FU/LV (n=974) 10 0 * * * * *p<0.001 Scheithauer et al. Ann Oncol 2003
17 Capecitabine is more toxic than infusional LV5FU
18 Seymour et al.
19 3 Adjuvant Trials with 5FU + Oxaliplatin Trial N Pts Treatment Data MOSAIC (NEJM 2004, ASCO 2005, ASCO 2007) Stage II/III 2246 FOLFOX-4 x 6 mos LV5FU2 x 6 mos 5-y DFS 6-y OS NSABP C-07 (JCO 2007) Stage II/III 2407 FLOX x 6 mos Bolus 5FULV w x 6 mos 6-y DFS 6-y OS NO16968 (JCO 2007, ECCO-ESMO 2009) Stage III 1886 XELOX x 6 mos Bolus 5FULV w/q4w x 6 mos 5-y-DFS (DFS 4-y ECCO-ESMO 2009)
20 MOSAIC: Treatment arms FOLFOX4: LV5FU2 + Oxaliplatin 85mg/m² D1 5FU bolus 400 mg/m2 D2 5FU bolus 400 mg/m2 LV 200 mg/m2 LV 200 mg/m2 5-FU 22h 600 mg/m2 5-FU 22h 600 mg/m2 stage II/III colon cancer R OXA D1 5FU bolus 400 mg/m2 D2 5FU bolus 400 mg/m2 LV5FU2 LV 200 mg/m2 5-FU 22h 600 mg/m2 LV 200 mg/m2 5-FU 22h 600 mg/m2 Cada 2 semanas, 6 meses de tratamiento (12 ciclos)
21 MOSAIC: treatment administration FOLFOX4 LV5FU2 Pacientes aleatorizados Pacientes tratados Número total de ciclos Media/Mediana ciclos 74.7% 86.5% Intensidad de dosis relativa mediana % Oxaliplatino 81 NA 5-FU 85 98
22 PFS (ITT) Probabilidad 1 0,9 3-años FOLFOX4 (n=1123) 77.8% LV5FU2 (n=1123) 72.9% 0,8 0,7 0,6 HR: 0.77 [ ] p < , André et al. NEJM 350;
23 PFS Stage III Probabilidad 1 0,9 3-años FOLFOX4 (n=672) 71.8% LV5FU2 (n=675) 65.5% 0,8 0,7 0,6 0,5 HR: 0.76 [ ] André et al. NEJM 350;
24 MOSAIC and NSABP C-07 Stage II and III (ITT) OS updated results with longer f-up DFS: 61.7 vs 67.5 HR = 0.82 (95% CI, ) DFS: 64.2 vs 69.4 HR = 0.82 (95% CI, ) André et al., JCO 2015; Yothers et al., JCO 2011
25 MOSAIC: safety NCI Gr 3 % FOLFOX4 LV5FU2 (n=1108) (n=1111) Trombocitopenia Neutropenia 41.0 ( Gr 4: 12.2) 4.7 Neutropenia Febril Sepsis Neutropénica Diarrea Estomatitis Vómitos Alergia Alopecia (Gr2) Neurosensory Mortalidad por cualquier causa
26 Adjuvant XELOX vs 5-FU/LV: NO16968 (XELOXA) Phase III trial Chemo/ radiotherapy-naive stage III colon 8 weeks since resection N=1886 R A N D O M I S A T I O N n=944 n=942 XELOX (6 months) capecitabine 1000mg/m 2 bid d1 14 oxaliplatin130mg/m 2 d1 q3w 8 cycles Bolus 5-FU/LV (6 months) Mayo Clinic [n=664] or Roswell Park [n=278] Primary endpoint: superiority of DFS Secondary endpoints: RFS, OS, tolerability Haller et al. ECCO-ESMO 2009
27 5-year DFS: benefit with XELOX maintained and increased over time 3-year DFS 4-year DFS 5-year DFS 1.0 XELOX 5-FU/LV 70.9% 68.4% 66.5% 62.3% 66.1% 59.8% Δ at 3 years: 4.5% HR=0.80 (95% CI: ) p= Δ at 4 years: 6.1% Δ at 5 years: 6.3% Years ITT population
28 Trend to improved OS with XELOX XELOX 5-FU/LV 5-year OS 77.6% 74.2% 0.6 Δ at 5 years: 3.4% HR=0.87 (95% CI: ) p= Years ITT population
29 Cross-trial comparison of MOSAIC and XELOXA: OS in stage III disease 1.0 NO16968 (XELOXA)* 5-yr OS XELOX (n=944) 77.6% MOSAIC 1 ** FOLFOX4 (n=672) 6-yr OS 72.9% Years *Median observation time: 57.0 months **Median follow-up: 81.9 months ITT population 1. André et al. JCO 2009
30 Safety Grade 3/4 AEs (%) XELOX n=938 5-FU/LV n=926 Febrile neutropenia Neutropenia Diarrhoea Stomatitis Nausea Vomiting HFS Neurosensory Schmoll et al. JCO 2007
31 Cross-trial comparison with MOSAIC Grade 3/4 AEs (%) XELOX n=938 FOLFOX4 (MOSAIC)* n=1108 Febrile neutropenia Neutropenia Diarrhoea Stomatitis Nausea Vomiting HFS Neurosensory Schmoll et al. JCO 2007 *MOSAIC trial: André et al. NEJM 2004
32
33 Stage II testing Les meves de ESMO I ESMO GI 2016 Les de la sessio ESMO 2017 del pavo angles
34 QUASAR Gill et al., JCO 2004; Quasar Col Group, Lancet 2007;
35 Introducción Mayor beneficio, pero limitado, en el grupo de pacientes con cáncer de colon estadio II de alto riesgo Factores de mal pronóstico ASCO pt4, alto grado histológico, perforación, ganglios analizados < 13 AJCC ESMO NIH pt4, alto grado histológico, invasión vascular, linfática o perineural, CEA preoperatorio elevado, margen radial afectado pt4, alto grado histológico, obstrucción o perforación, ganglios analizados < 12, invasión vascular, linfática o perineural pt4, alto grado histológico o diferenciación coloide o en anillo de sello, CEA preoperatorio elevado, aneuploidía, delección de 17p o 18q, fase S proliferación elevada Benson et al., JCO 2004; Compton et al., Cancer 2000; Labianca et al.,ann Oncol 2010; JAMA 1990
36 T4MSI Variable HR (95%, CI) T stage (T4 vs T3) 1.73 ( ) No of LN examined 0.79 ( ) MSI (MSI-H vs MS-L/S) 0.54 ( ) BRAF 1.17 ( ) KRAS 1.05 ( ) Variable HR (95%, CI) T stage (T4 vs T3) 1.94 ( ) No of LN examined 0.73 ( ) MSI (MSI-H vs MS-L/S) 0.43 ( ) BRAF 1.56 ( ) KRAS 1.10 ( ) Roth et al., J Natl Cancer Inst 2012
37 Addition of OXL is not supported in Stage II (MOSAIC and NSABP C-07) DFS: 73.6 vs 75.2 HR = 0.89 (95% CI, ) DFS: 80.1 vs 82.1 HR = 1.04 (95% CI, ) André et al., JCO 2015; Yothers et al., JCO 2011
38 What s the question in Stage III
39 IDEA: adjuvant 3 vs 6 months Folfox/Xelox
40 IDEA Trials Summary Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
41 Non-inferiority Hypothesis Testing Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
42 Results: RFS/DFS Overall Population Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
43 Primary Efficacy Analysis Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
44 Primary DFS Analysis (mitt), cont. Presented By Qian Shi at 2017 ASCO Annual Meeting
45 DFS Comparison by Risk Groups, cont. Presented By Qian Shi at 2017 ASCO Annual Meeting
46 DFS Comparison by Regimen, cont. Presented By Qian Shi at 2017 ASCO Annual Meeting
47 DFS Comparison by Risk Group and Regimen Presented By Qian Shi at 2017 ASCO Annual Meeting
48 DFS Comparison by Risk Group and Regimen, cont. Presented By Qian Shi at 2017 ASCO Annual Meeting
49 CÁNCER COLORRECTAL Grothey A, et al. LBA21. ESMO 2017
50 What about the elderly population Do they need or deserve the same treat Sharper Balance toxicity-efficacy and life expectancy
51 ACCENT DATABASE 5FU CHX Sargent et al, 2001
52 Upper limit 75y as per inclusion criteria female patients years had the same oxaliplatin benefit as younger patients DFS and OS benefits in patients years were similar to those of younger patients for the first 3 years of follow-up, but were lost later on due to deaths from other causes.
53
54
55
56 Oral capecitabine improved outcomes when compared with bolus 5-FU/LV in the X-ACT trial in patients 70 years
57
58 Summary of the evidence LV5FU2 vs bolus 5FULV vs capecitabine LV5FU2 infusion non-inferior and better safety Capecitabine non-inferior (maybe better) than bolus 5FULV, better safety than bolus, but worse than LV5FU2 Oxaliplatin Folfox/Xelox adds both efficacy and toxicity in stage III Stage II high risk (T4MSS): 5FULV2 (or capecitabine) 3 months Xelox is an option in low risk stage III (T3N1) Elderly Balance between life expectancy, efficacy and safety Geriatric assesment
59 Questions?
60 Questions? 75 y-old female T4N1 No comorbidities, good surgical recovery PS 0 How would you treat her
61 Questions? 75 y-old male T4N0 No comorbidities PS 0 How would you treat him
62 Questions? 75 y-old male T4N0 No comorbidities PS 0 How would you treat him If MSI?
63 Prognostic signatures in early-stage CRC <br />are not predictive of chemotherapy benefit Presented By Rodrigo Dienstmann at 2017 ASCO Annual Meeting
64 Prognosis in early-stage CRC is dictated by microenvironment features Presented By Rodrigo Dienstmann at 2017 ASCO Annual Meeting
65 Slide 29 Presented By Rodrigo Dienstmann at 2017 ASCO Annual Meeting
Disclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationProgress and Challenges in the Adjuvant Treatment of Stage II & III Colon Cancer
Progress and Challenges in the Adjuvant Treatment of Stage II & III Colon Cancer Professor Eva Segelov Monash Health and Monash University (with thanks to A/P Jeremy Shapiro) Melbourne, Australia Apr 2017
More informationAdjuvant treatment for stage III colon cancer
ESMO Preceptorship Programme Rectal cancer Singapur November 2017 Adjuvant treatment for stage III colon cancer Andrés Cervantes Disclosures Consulting and advisory services, speaking or writing engagements,
More informationTerapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia
Terapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia Temario Generalidades Adyuvancia en colon y recto FU / Capecitabina
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationS u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r
EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationAdjuvant therapy in older adults: controversies and challenges - Colorectal cancer -
International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie
More informationIs There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?
Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationHot Topic in tema di neoplasie del Colon: Durata ottimale della chemioterapia adiuvante nei tumori del Colon
Convegno Nazionale AIOM Giovani 2018 News in Oncology Hot Topic in tema di neoplasie del Colon: Durata ottimale della chemioterapia adiuvante nei tumori del Colon Daniele Rossini U.O. di Oncologia Medica
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationWhere are we in 2013?
The Use of Gene Profile Testing in the Adjuvant Therapy of Stages II & III Colon Cancer: Where are we in 2013? Howard S. Hochster, MD Professor of Medicine, Yale School of Medicine Associate Director,
More informationOptimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles YES
Optimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles YES Bassel F. El-Rayes 1 Background Standard of care for resected stage III colon cancer is six months of adjuvant oxaliplatin-based therapy
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationIl paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
More informationSIOG CRC Guidelines D Papamichael MB BS FRCP Cyprus Oncology Centre SIOG 2014 Special SIOG Guidelines Session
SIOG CRC Guidelines D Papamichael MB BS FRCP Cyprus Oncology Centre SIOG 2014 Special SIOG Guidelines Session Lisbon October 25 th Outline Background Surgery in older adults Adjuvant therapy - Single agent
More informationBest of ASCO 2009 / GI
Best of ASCO 2009 / GI Santa Monica, CA J. Randolph Hecht, M.D. Professor of Clinical Medicine Director, UCLA GI Oncology Program David Geffen School of Medicine at UCLA Financial Disclosures I have no
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationManagement of early rectal cancer: Any role for adjuvant chemotherapy
Management of early rectal cancer: Any role for adjuvant chemotherapy Andrés Cervantes Professor of Medicine CURRENTS CONCEPTS IN RECTAL CANCER DIAGNOSIS AND THERAPY TME surgery Optimal staging by MRI
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationCOLORECTAL CANCER. Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program
COLORECTAL CANCER Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program Rectal Cancer Adjuvant therapy No single study specific to rectal cancer
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationColorectal Cancer Update Dr. Barb Melosky
Colorectal Cancer Update 2017 Dr. Barb Melosky bmelosky@bccancer.bc.ca Disclosure Research Support/P.I. Honoraria/Advisory Board Bayer Roche, Amgen, Bayer, Lilly Objectives 1) Demonstrate knowledge of
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationThe role of Maintenance treatment Appropriate endpoints according to ESMO consensus
ESMO Preceptorship Programme Colorectal Cancer Singapore-October 20-22 2016 JY Douillard, MD, PhD, CMO ESMO The role of Maintenance treatment Appropriate endpoints according to ESMO consensus MAINTENANCE
More informationThe International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice
Editorial The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Marwan Fakih Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationMOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators
MOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators Thierry André, Armand de Gramont, Benoist Chibaudel, Annemilaï Raballand,
More informationWhat s New? Dr. Barbara Melosky
Metastatic Colorectal o Carcinoma a What s New? Dr. Barbara Melosky Objectives Review any recent changes regarding treatment t t options for mcrc Discuss the common and expected toxicities of treatment
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationAdjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration
JBUON 2018; 23(3): 568-573 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Adjuvant chemotherapy for high-risk stage II and stage III colon cancer:
More informationtrial update clinical
clinical trial update by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UMPC Cancer Centers In order to provide the most up-to-date and efficacious care to their patients, oncologists must
More informationLindsay A. Renfro, Daniel J. Sargent. Statistics in Oncology Clinical Trials
Page 1 of 11 Editor s note: The special column Statistics in Oncology Clinical Trials is dedicated to providing state-of-the-art review or perspectives of statistical issues in oncology clinical trials.
More informationChemotherapy options and outcomes in older adult patients with colorectal cancer
Critical Reviews in Oncology/Hematology 72 (2009) 155 169 Chemotherapy options and outcomes in older adult patients with colorectal cancer Muhammad W. Saif a,, Stuart M. Lichtman b a Yale University School
More informationWill All Adjuvant Therapy Trials Be Negative in RCC?
Will All Adjuvant Therapy Trials Be Negative in RCC? Tim Eisen Eleventh European International Kidney Cancer Symposium 29-30 April 2016 Crowne Plaza Barcelona Fira Center, Barcelona, Spain Tim Eisen -
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationPancreatic Ca Update
Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine E-mail:crochali@wakehealth.edu
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationFabienne Warmerdam Zuyderland
GE Fabienne Warmerdam Zuyderland Disclosure ASCO 2017 travelgrant Pfizer CRC ADJUVANT Less is more? More is More! 1 Less is more? Perspectief INT-0035 stadium III (niets vs 5-FU) 6.5-jaars OS 46% vs. 60%
More informationNuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos?
Nuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos? Prof. Dr. Paulo M. Hoff Instituto do Câncer do Estado de São Paulo - ICESP Faculdade de Medicina Universidade de São Paulo (USP) Conflicts
More informationTHE BEST OF ESMO 2016
THE BEST OF ESMO 2016 Colorectal cancer Pr Julien TAIEB, Sorbonne Paris Cité and Paris Descartes University Georges Pompidou European Hospital Paris, FRANCE esmo.org DISCLOSURES JT has received research
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 State of the art: Radio- /chemotherapy for rectal cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationRECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER
RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER SUNAKAWA, Y, 1 BEKAIISAAB, T, 2 AND STINTZING, S. 3 SELECTED HIGHLIGHTS
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
COME HOME Rectal Cancer Pathway V8, April 2015 Diagnostic Workup: Bethesda Criteria: Pathology Review All patients H&P All patients Biopsy All patients Colonoscopy All patients CEA All Patients Chest/Abdominal/Pelvic
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More information2/20/14& Medical Management of Colon and Rectal Cancer: An Overview. Outline / Learning Objectives. How common is colon cancer?
Medical Management of Colon and Rectal Cancer: An Overview Jonathan Grim, MD, PhD VA Puget Sound Health Care System Fred Hutchinson Cancer Research Center UW Medicine Outline / Learning Objectives Epidemiology
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More information/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W
癌症診療指引33 Adjuvant therapy of colon cancer mfolfox6 Oxaliplatin 85 1 Q2W 1-3 FOLFOX4 Oxaliplatin 85 1 Q2W 9 Leucovorin 200 1-2 Q2W 5-FU 400 1-2 Q2W 5-FU 600 1-2 Q2W FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin
More informationAdjuvant therapy in colon cancer: which treatment in 2005?
Annals of Oncology 16 (Supplement 4): iv69 iv73, 2005 doi:10.1093/annonc/mdi911 Adjuvant therapy in colon cancer: which treatment in 2005? F. Di Costanzo* & L. Doni Medical Oncology Unit, Department of
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationHow Old is Too Old for Chemotherapy in Early C olon Colon Cancer: Role of Geriatric Assessments Winson Y. Cheung, MD, MPH, FRCPC
How Old is Too Old for Chemotherapy in Early Colon Cancer: Role of Geriatric Assessments Winson Y. Cheung, MD, MPH, FRCPC British Columbia Cancer Agency - Vancouver CAGPO - October 20, 2013 1 About Me
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationProgress towards an individualized approach to therapy: colorectal cancer
Progress towards an individualized approach to therapy: colorectal cancer Alan P. Venook, M.D. University of California, SF GIST: PET change after 4 weeks imatinib Multiple liver and upper abdominal 18
More informationTreatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations
Treatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations D Papamichael MB BS FRCP On behalf of the SIOG CRC in the Elderly Task Force Madrid 10/11/07 8 th Meeting of the International
More informationColorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More information療指引 34 Adjuvant Therapy of Colon Cancer
療指引 34 Adjuvant Therapy of Colon Cancer mfolfox6 Oxaliplatin 85 1 Q2W 1~3, 10 FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin 500 1,8,15,22,29,35 Q8W 5-FU 500 1,8,15,22,29,35 Q8W Capecitabine Capecitabine
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationUnderstanding predictive and prognostic markers
Understanding predictive and prognostic markers Professor Aimery de Gramont Chairman of ARCAD Foundation and GERCOR, Paris FRANCE Understanding predictive and prognostic markers Aimery de Gramont Prognostic
More informationWeekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection
Original article Annals of Oncology 15: 568 573, 2004 DOI: 10.1093/annonc/mdh134 Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after
More informationUnresectable or boarderline resectable disease
ESMO Preceptorship Colorectal Cancer Nov 2016 Barcelona Unresectable or boarderline resectable disease Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West German Cancer Center (NWTZ) Learning
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationAdjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma
JBUON 2014; 19(4): 906-912 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Adjuvant chemotherapy outcomes in patients over 65 years with early
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationRESEARCH ARTICLE. Joanne Chiu 1, Vikki Tang 1, Roland Leung 1, Hilda Wong 1, Kin Wah Chu 2, Jensen Poon 3, Richard J Epstein 4, Thomas Yau 1,3,5 *
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.11.6585 Adjuvant XELOX in Asian Patients with Colorectal Cancer RESEARCH ARTICLE Efficacy and Tolerability of Adjuvant Oral Capecitabine plus Intravenous Oxaliplatin
More informationCHEMOTHERAPY FOR COLON CANCER OUTLINE OF TODAY S TALK. Colon Cancer Epidemiology 11/6/2012 GATRA/GCCR FALL CONFERENCE NOVEMBER 14 16, 2012
CHEMOTHERAPY FOR COLON CANCER JONATHAN C. BENDER,MD MEDICAL DIRECTOR OF PIEDMONT FAYETTE CANCER CENTER OUTLINE OF TODAY S TALK 1. Overview of Colon Cancer in the US 2. Colon Cancer staging and risks of
More informationAdjuvant Treatment of Colorectal Cancer
Adjuvant Treatment of Colorectal Cancer Adjuvant Treatment of Colorectal Cancer Brian M. Wolpin, MD; Jeffrey A. Meyerhardt, MD, MPH; Harvey J. Mamon, MD, PhD; Robert J. Mayer, MD Dr. Wolpin is Instructor
More informationKolorektalni karcinom- novosti u liječenju. PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić
Kolorektalni karcinom- novosti u liječenju PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić Kolorektalni karcinomnovosti u liječenju PANEL : Maja Banjin, Janja Ocvirk, Borislav
More informationThe left versus right colon cancer story What is the truth?
The left versus right colon cancer story What is the truth? Prof. V. Heinemann CCC LMU, Klinikum Grosshadern Ludwig-Maximilian-University of Munich, Germany Three stages of truth (Schopenhauer) Ridicule
More informationColon, Rectum, and Appendix
Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline
More informationColon, Rectum, and Appendix. Presentation Outline. Overview Tumor Characteristics
Colon, Rectum, and Appendix 2011 Reporting Requirements and CSv02.03.02 NCCN/ASCO Treatment Guidelines by Stage FCDS 2011 Educational Webcast Series September 15, 2011 Steven Peace, CTR Presentation Outline
More information